药学学报, 2022, 57(2): 271-276
引用本文:
刘可欣#, 吴瑞琳#, 袁涛, 蒲凯悦, 何俏军, 朱虹*, 杨波*. KRASG12C抑制剂抗肿瘤耐药机制及克服策略研究进展[J]. 药学学报, 2022, 57(2): 271-276.
LIU Ke-xin#, WU Rui-lin#, YUAN Tao, PU Kai-yue, HE Qiao-jun, ZHU Hong*, YANG Bo*. Recent advances in mechanisms of KRASG12C inhibitors anti-tumor resistance and relevant overcoming strategies[J]. Acta Pharmaceutica Sinica, 2022, 57(2): 271-276.

KRASG12C抑制剂抗肿瘤耐药机制及克服策略研究进展
刘可欣#, 吴瑞琳#, 袁涛, 蒲凯悦, 何俏军, 朱虹*, 杨波*
浙江大学药学院, 浙江 杭州 310058
摘要:
KRAS是人类癌症中最常出现突变的致癌基因之一。尽管长期以来诸多研究致力于直接或间接靶向KRAS的干预策略研究,但仍面临难以靶向、效果受限的问题,因此KRAS一直被认为是"不可成药"的靶点蛋白。最近,KRASG12C突变亚型特异性抑制剂研究取得重大突破,部分KRASG12C抑制剂相继进入临床试验,包括阿达格拉西布(adagrasib)和索托拉西(sotorasib)等,且已显示出显著的疗效,为KRASG12C突变驱动的恶性肿瘤患者带来了希望。RAS通路其他抑制剂的研发经验表明,快速产生的耐药性会限制药物的作用,而目前研究已经发现KRASG12C抑制剂亦存在明显的耐药问题。本文概述KRASG12C抑制剂的研发现状,讨论其耐药的机制,为探索克服其耐药的干预策略提供思路和方向。
关键词:    KRAS      G12C突变      癌基因      靶向治疗      耐药     
Recent advances in mechanisms of KRASG12C inhibitors anti-tumor resistance and relevant overcoming strategies
LIU Ke-xin#, WU Rui-lin#, YUAN Tao, PU Kai-yue, HE Qiao-jun, ZHU Hong*, YANG Bo*
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
Abstract:
KRAS is one of the most frequently mutated human oncogenes. In spite of mounting efforts on the development of direct or indirect inhibition targeting KRAS, little has been achieved because of insurmountable difficulties, titling KRAS "undruggable". Recently, subtype-specific inhibitors have shown great hope. Some KRASG12C inhibitors have entered clinical trials, including adagrasib and sotorasib, and have shown preliminary clinical effectiveness. Experiences from the inhibitors targeting the downstream factors of RAS pathways show that the anticancer activity of these drugs will be limited due to the development of drug resistance. Preclinical studies of KRASG12C inhibitors have revealed that the application of these agents might be hampered by the drug resistance issue. The current review aims to describe the current status of KRASG12C inhibitors, and discuss the mechanisms underlying KRASG12Cinhibitor resistance, so as to provide the clues for the combat of drug resistance.
Key words:    KRAS    G12C mutation    oncogene    targeted therapy    drug resistance   
收稿日期: 2021-07-25
DOI: 10.16438/j.0513-4870.2021-1093
基金项目: 浙江省自然科学基金资助项目(LR19H310002);浙江省重点研发计划(2021C03042).
通讯作者: 朱虹,Tel:86-571-88208400,E-mail:hongzhu@zju.edu.cn;杨波,E-mail:yang924@zju.edu.cn
Email: hongzhu@zju.edu.cnyang924@zju.edu.cn
相关功能
PDF(1345KB) Free
打印本文
0
作者相关文章
刘可欣#  在本刊中的所有文章
吴瑞琳#  在本刊中的所有文章
袁涛  在本刊中的所有文章
蒲凯悦  在本刊中的所有文章
何俏军  在本刊中的所有文章
朱虹*  在本刊中的所有文章
杨波*  在本刊中的所有文章

参考文献:
[1] Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy[J]. Acta Pharm Sin B, 2019, 9:871-879.
[2] Chen S, Li F, Xu D, et al. The function of RAS mutation in cancer and advances in its drug research[J]. Curr Pharm Des, 2019, 25:1105-1114.
[3] Thein KZ, Biter AB, Hong DS. Therapeutics targeting mutant KRAS[J]. Annu Rev Med, 2021, 72:349-364.
[4] Kim D, Xue JY, Lito P. Targeting KRAS (G12C):from inhibitory mechanism to modulation of antitumor effects in patients[J]. Cell, 2020, 183:850-859.
[5] Pai EF, Kabsch W, Krengel U, et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation[J]. Nature, 1989, 341:209-214.
[6] Dunnett-Kane V, Nicola P, Blackhall F, et al. Mechanisms of resistance to KRASG12C inhibitors[J]. Cancers, 2021, 13:151.
[7] Haigis KM. KRAS alleles:the devil is in the detail[J]. Trends Cancer, 2017, 3:686-697.
[8] Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors[J]. Cancer Cell, 2020, 37:543-550.
[9] Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS:mission possible?[J]. Nat Rev Drug Discov, 2014, 13:828-851.
[10] Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance[J]. J Cell Sci, 2016, 129:1287-1292.
[11] Xu YZ, Wen H, Cui HQ. Research progress of KRAS inhibitors[J]. Acta Pharm Sin (药学学报), 2021, 56:1562-1570.
[12] Li X, Wang YJ, Liu PY. Recent advancement in targeting the KRAS-G12C mutant for cancer therapy[J]. Acta Pharm Sin (药学学报), 2021, 56:374-382.
[13] Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor[J]. Cell, 2018, 172:578-589.
[14] Canon J, Rex K, Saiki AY, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity[J]. Nature, 2019, 575:217-223.
[15] Hallin J, Engstrom LD, Hargis L, et al. The KRAS (G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J]. Cancer Discov, 2020, 10:54-71.
[16] Ostrem JM, Peters U, Sos ML, et al. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions[J]. Nature, 2013, 503:548-551.
[17] Jänne PA, Rybkin II, Spira AI, et al. 3LBA late breaking- KRYSTAL-1:activity and safety of adagrasib (MRTX849) in advanced/metastatic non-small-cell lung cancer (NSCLC) harboring KRAS G12C mutation[J]. Eur J Cancer, 2020, 138:S1-S2.
[18] Jiao D, Yang S. Overcoming resistance to drugs targeting KRAS (G12C) mutation[J]. Innovation, 2020, 1:100035.
[19] Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival[J]. Cancer Cell, 2009, 15:489-500.
[20] Muzumdar MD, Chen PY, Dorans KJ, et al. Survival of pancreatic cancer cells lacking KRAS function[J]. Nat Commun, 2017, 8:1090.
[21] Misale S, Fatherree JP, Cortez E, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition[J]. Clin Cancer Res, 2019, 25:796-807.
[22] Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation-specific KRAS (G12C) inhibition[J]. Nature, 2020, 577:421-425.
[23] Paul MD, Hristova K. The RTK interactome:overview and perspective on RTK heterointeractions[J]. Chem Rev, 2019, 119:5881-5921.
[24] Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer[J]. Mol Cancer, 2018, 17:58.
[25] Ryan MB, Fece de la Cruz F, Phat S, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS (G12C) inhibition[J]. Clin Cancer Res, 2020, 26:1633-1643.
[26] Lito P, Solomon M, Li LS, et al. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism[J]. Science, 2016, 351:604-608.
[27] Fedele C, Li S, Teng KW, et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling[J]. J Exp Med, 2021, 218:e20201414.
[28] Dance M, Montagner A, Salles JP, et al. The molecular functions of SHP2 in the RAS/mitogen-activated protein kinase (ERK1/2) pathway[J]. Cell Signal, 2008, 20:453-459.
[29] Molina-Arcas M, Moore C, Rana S, et al. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer[J]. Sci Transl Med, 2019, 11:eaaw7999.
[30] Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS (G12C) inhibition in colorectal cancer[J]. Cancer Discov, 2020, 10:1129-1139.
[31] Tanaka N, Lin JJ, Li C, et al. Clinical acquired resistance to KRAS (G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation[J]. Cancer Discov, 2021, 11:1913-1922.
[32] Adachi Y, Ito K, Hayashi Y, et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2020, 26:5962-5973.
[33] Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis[J]. Clin Transl Med, 2015, 4:6.
相关文献:
1.李歆, 王义俊, 刘平羽.特异靶向KRAS-G12C突变的抗肿瘤药物研究进展[J]. 药学学报, 2021,56(2): 374-382